Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.95 USD
Change Today +0.0097 / 1.03%
Volume 2.0M
XOMA On Other Exchanges
As of 8:10 PM 10/8/15 All times are local (Market data is delayed by at least 15 minutes).

xoma corp (XOMA) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/28/14 - $5.95
52 Week Low
08/24/15 - $0.69
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for XOMA CORP (XOMA)

Related News

No related news articles were found.

xoma corp (XOMA) Related Businessweek News

No Related Businessweek News Found

xoma corp (XOMA) Details

XOMA Corporation discovers and develops antibody-based therapeutics in the United States, Europe, and the Asia Pacific. The company’s lead product candidate includes gevokizumab, a proprietary humanized allosteric-modulating monoclonal antibody that binds to the inflammatory cytokine interleukin-1 beta, which is in Phase III clinical trial for NIU and Behçet’s disease uveitis, pyoderma gangrenosum, active non-infectious anterior scleritis, autoimmune inner ear disease, and cardiovascular diseases, as well as diseases under the neutrophilic dermatoses designation, Schnitzler syndrome, and other diseases; and various proof-of-concept studies comprising polymyositis/dermatomyositis, Schnitzler syndrome, and giant cell arteritis. Its proprietary product pipeline also comprises XOMA metabolic activating, sensitizing, and deactivating/antagonizing antibodies that are in preclinical stage for the treatment of diabetes patients; XOMA 3AB, a multi-antibody product for the treatment of human botulism poisoning; and XOMA 629, a topical anti-bacterial product for the treatment of human immune system. In addition, the company licenses antibody discovery, optimization, and development technologies, including Antibody Discovery Advanced Platform Technologies, ModulX, and OptimX. It has collaboration and licensing agreements with Les Laboratoires Servier; National Institute of Allergy and Infectious Diseases; Takeda Pharmaceutical Company Limited; Novartis AG; Pfizer Inc.; Symplmed Pharmaceuticals, LLC; and Texas A&M University. The company was founded in 1981 and is headquartered in Berkeley, California.

176 Employees
Last Reported Date: 08/10/15
Founded in 1981

xoma corp (XOMA) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $569.5K
Founder, Chief Scientific Officer, Executive ...
Total Annual Compensation: $250.3K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $411.0K
Compensation as of Fiscal Year 2014.

xoma corp (XOMA) Key Developments

XOMA Corporation and Novartis International Pharmaceutical Ltds Enters into License Agreemen

XOMA Corporation and Novartis International Pharmaceutical Ltd. entered into license agreement pursuant to which the company, acting through its wholly-owned subsidiary XOMA (US) LLC, has granted to Novartis an exclusive, world-wide, royalty-bearing license to the company’s anti-transforming growth factor beta antibody program. Novartis will have worldwide rights to the Program and will be solely responsible for the development and commercialization of antibodies and products containing antibodies arising from the Program. The company will transfer certain proprietary know-how, materials and inventory relating to the Program to Novartis. Under the License Agreement, the company will receive a $37 million upfront payment. Based on the achievement of pre-specified criteria, the company is eligible to receive up to $480 million in development, regulatory and commercial milestones. The company is also eligible to receive royalties on sales of licensed products, which are tiered based on sales levels and range from a mid-single digit percentage rate to up to a low double-digit percentage rate. Novartis' obligation to pay development and commercialization milestones will continue for so long as Novartis is developing or selling products under the License Agreement, subject to the maximum milestone payment amounts set forth above. Novartis' obligation to pay royalties with respect to a particular product and country will continue for the longer of the date of expiration of the last valid patent claim covering the product in that country, or ten years from the date of the first commercial sale of the product in that country. The License Agreement contains customary termination rights relating to material breach by either party. Novartis also has a unilateral right to terminate the License Agreement on an antibody-by-antibody and country-by-country basis or in its entirety on one hundred eighty days' notice.

XOMA Corporation Receives Non-Compliance Letter From NASDAQ

XOMA Corporation received a letter from the staff of The NASDAQ Stock Market LLC (“NASDAQ”) on September 4, 2015 providing notification that, for the previous 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Global Market under NASDAQ’s Listing Rule 5450(a)(1), requiring a minimum bid price of $1.00 per share (the “Minimum Bid Price Requirement”). The notification of noncompliance has no immediate effect on the listing or trading of the Company’s common stock on the NASDAQ Global Market. In accordance with Nasdaq Listing Rule 5810(c)(3)(A) , if during the 180 calendar days following the date of the notification, or prior to March 2, 2016, the closing bid price of the Company’s common stock is at or above $1.00 for a minimum of 10 consecutive business days, the Staff will provide the Company with written confirmation of compliance. If the Company does not achieve compliance with the Minimum Bid Price Requirement by March 2, 2016, the Company may be eligible for an additional 180 calendar days compliance period if it elects to transfer to the Nasdaq Capital Market, so as to take advantage of the additional compliance period offered on that market. To qualify, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the bid price requirement, and would need to provide written notice of its intention to cure the deficiency during the second compliance period. However, if it appears to the Staff that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, the Staff would notify the Company that its securities would be subject to delisting. In the event of such notification, the Company may appeal the Staff’s determination to delist its securities, but there can be no assurance the Staff would grant the Company’s request for continued listing. The Company intends to monitor the closing bid price of its common stock and may, if appropriate, consider implementing available options to regain compliance with the Minimum Bid Price Requirement under the NASDAQ Listing Rules.

XOMA CORP. Pledges 30% Workforce Reduction

XOMA CORP. pledged a 30% workforce reduction on 19 August, 2015, resulting in the termination of 58 positions across all areas of the organization, leading to a workforce of 134 employees. XOMA completed this action on 21 August, 2015. Affected workers can receive severance payments and payments of their COBRA premiums for up to 9 months.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
XOMA:US $0.95 USD +0.0097

XOMA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
arGEN-X BV €9.21 EUR -0.09
BioInvent International AB kr2.86 SEK -0.03
Intrexon Corp $34.77 USD +1.06
MorphoSys AG €61.35 EUR +0.155
PDL BioPharma Inc $5.17 USD 0.00
View Industry Companies

Industry Analysis


Industry Average

Valuation XOMA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 7.8x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact XOMA CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at